Brief: Akeso Announced Completion Of Patient Enrollment In Phase 3 Trial Of Ivonescimab (Pd-1/Vegf) Versus Pembrolizumab In First-Line Pd-L1 Positive Advanced Nsclc
29/08/2023 13:09
Aug 29 (Reuters) - Akeso Inc 9926.HK :
* AKESO ANNOUNCED COMPLETION OF PATIENT ENROLLMENT IN PHASE
3
TRIAL OF IVONESCIMAB (PD-1/VEGF) VERSUS PEMBROLIZUMAB IN
FIRST-LINE PD-L1 POSITIVE ADVANCED NSCLC
Source text for Eikon: ID:nPn6wVNhFa
Further company coverage: 9926.HK
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals